Loading…
Sai Life Sciences (SAILIFE)₹1,837+5.32%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Sai Life Sciences reported sales of ₹555 Cr, up 11.6% from Jun 2025, and net profit of ₹72.91 Cr, up 21.6% year on year. For the year to Mar 2026, sales were ₹2,197 Cr and net profit ₹349 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 385 | 440 | 281 | 397 | 440 | 581 | 497 | 538 | 557 | 603 | 555 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96.24 | 125 | 26.07 | 102 | 120 | 158 | 121 | 146 | 188 | 178 | 148 |
| OPM % | 25.0% | 28.0% | 9.0% | 26.0% | 27.0% | 27.0% | 24.0% | 27.0% | 34.0% | 29.0% | 27.0% |
| Other Income | 11.03 | 3.01 | 8.02 | 10.03 | 9.03 | 10.02 | 10.03 | 15.04 | 0.00 | 16.05 | 4.01 |
| Interest | 23.08 | 21.08 | 21.08 | 21.08 | 23.09 | 11.03 | 12.04 | 9.04 | 10.04 | 8.03 | 8.03 |
| Depreciation | 31.02 | 31.02 | 31.05 | 36.05 | 34.06 | 37.08 | 38.09 | 40.08 | 44.06 | 45.09 | 46.04 |
| Profit before tax | 52.85 | 75.72 | −17.95 | 54.81 | 71.83 | 119 | 80.79 | 112 | 134 | 138 | 97.69 |
| Tax % | 24.9% | 26.0% | −25.1% | 25.0% | 25.0% | 25.9% | 24.9% | 24.9% | 24.9% | 24.9% | 24.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −5.99 | 0.00 | 0.00 |
| Net Profit | 39.96 | 55.90 | −13.99 | 41.93 | 53.93 | 87.95 | 59.95 | 83.92 | 99.94 | 104 | 72.91 |
| EPS (Rs) | — | — | — | — | 2.60 | 4.25 | 2.91 | 4.01 | 4.76 | 4.93 | 3.46 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 696 | 727 | 762 | 872 | 1,220 | 1,468 | 1,699 | 2,197 | 2,253 |
| Expenses | 520 | 558 | 593 | 742 | 1,048 | 1,177 | 1,284 | 1,560 | 1,592 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 288 | 411 | 633 | 661 |
| OPM % | 25.0% | 23.0% | 22.0% | 15.0% | 14.0% | 20.0% | 24.0% | 29.0% | 29.3% |
| Other Income | 6.01 | 18.05 | 27.08 | 28.09 | 27.08 | 29.07 | 35.07 | 41.13 | 35.10 |
| Interest | 24.10 | 22.07 | 33.12 | 54.22 | 81.34 | 88.34 | 78.24 | 39.14 | 35.14 |
| Depreciation | 44.06 | 55.11 | 80.17 | 90.08 | 99.20 | 119 | 139 | 167 | 175 |
| Profit before tax | 113 | 109 | 81.68 | 9.97 | 15.95 | 109 | 227 | 464 | 482 |
| Tax % | 35.0% | 29.9% | 25.0% | 35.9% | 39.0% | 24.0% | 24.9% | 24.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 10.97 | 0.00 | 0.00 | −0.99 | −5.99 | −5.99 |
| Net Profit | 72.98 | 75.96 | 60.95 | 5.99 | 9.99 | 82.85 | 170 | 349 | 361 |
| EPS (Rs) | — | — | — | — | — | — | 8.17 | 16.53 | 17.16 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 1,117.0% | 676.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.04 | 16.03 | 17.05 | 18.04 | 18.01 | 18.03 | 21.07 | 21.05 |
| Reserves | 702 | 776 | 843 | 860 | 868 | 955 | 2,103 | 2,460 |
| Borrowings | 249 | 304 | 637 | 752 | 932 | 927 | 352 | 288 |
| Other Liabilities | 246 | 311 | 316 | 524 | 356 | 357 | 662 | 851 |
| Total Liabilities | 1,213 | 1,407 | 1,814 | 2,154 | 2,174 | 2,258 | 3,138 | 3,620 |
| Fixed Assets | 372 | 640 | 700 | 751 | 1,036 | 1,179 | 1,486 | 1,813 |
| CWIP | 116 | 91.22 | 247 | 411 | 151 | 107 | 124 | 271 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 2.01 | 2.01 | 50.08 |
| Other Assets | 724 | 676 | 867 | 993 | 985 | 970 | 1,525 | 1,486 |
| Inventories | 44.07 | 44.07 | 76.21 | 127 | 140 | 87.14 | 119 | 151 |
| Trade receivables | 234 | 270 | 205 | 242 | 283 | 255 | 354 | 373 |
| Cash & equivalents | 249 | 97.68 | 75.80 | 130 | 85.77 | 159 | 463 | 111 |
| Total Assets | 1,213 | 1,407 | 1,814 | 2,154 | 2,174 | 2,258 | 3,138 | 3,620 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 129 | 116 | −36.07 | 105 | 220 | 263 | 315 | 510 |
| Cash from investing activity | −158 | −261 | −259 | −102 | −98.74 | −190 | −534 | −394 |
| Cash from financing activity | 267 | −3.99 | 295 | 71.75 | −200 | −94.64 | 300 | −124 |
| Net cash flow | 239 | −150 | −1.01 | 75.03 | −80.02 | −24.04 | 79.14 | −10.01 |
| Capex | 158 | 272 | 262 | 207 | 113 | 182 | 369 | 592 |
| Free cash flow | −28.05 | −157 | −298 | −102 | 148 | 82.09 | −55.10 | −83.08 |
| CFO / OP % | 90.0% | 81.0% | −13.0% | 90.0% | 132.0% | 96.1% | 82.1% | 87.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 124 | 137 | 100 | 103 | 86 | 65 | 77 | 63 |
| Inventory days | 87 | 80 | 128 | 180 | 122 | 73 | 94 | 98 |
| Days payable | 208 | 259 | 231 | 280 | 181 | 114 | 254 | 183 |
| Cash conversion cycle | 1 | −43 | −4 | 2 | 25 | 22 | −83 | −24 |
| Working capital days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 78 |
| ROCE % | — | 13.0% | 9.0% | 3.0% | 6.0% | 11.0% | 14.0% | 20.0% |
For the Jun 2026 quarter, Sai Life Sciences reported sales of ₹555 Cr, up 11.6% year on year and net profit of ₹72.91 Cr, up 21.6% year on year. The operating margin was 27.0%.
Sai Life Sciences' sales for the year to Mar 2026 were ₹2,197 Cr; over the last twelve months they were ₹2,253 Cr.
Net profit for the year to Mar 2026 was ₹349 Cr, and ₹361 Cr over the last twelve months. Earnings per share over the same trailing period were ₹17.16.
Sai Life Sciences reported borrowings of ₹288 Cr at Mar 2026, against cash and equivalents of ₹111 Cr.
Cash from operations was ₹510 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹83.08 Cr.